PubMed:27028795 / 105-302 JSONTXT

{"project":"Preeclampsia","denotations":[{"id":"PD-Preeclampsia-B_T2","span":{"begin":184,"end":196},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"To evaluate KRYPTOR assays for circulating soluble fms-like tyrosine kinase-1 (sFlt1) and placental growth factor (PlGF) in risk assessment of adverse outcomes in women with suspected preeclampsia."}

{"project":"Preeclampsia-compare","denotations":[{"id":"PD-Preeclampsia-B_T2","span":{"begin":184,"end":196},"obj":"ORPHA:275555"}],"namespaces":[{"prefix":"ORPHA","uri":"www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN\u0026Expert="}],"text":"To evaluate KRYPTOR assays for circulating soluble fms-like tyrosine kinase-1 (sFlt1) and placental growth factor (PlGF) in risk assessment of adverse outcomes in women with suspected preeclampsia."}

{"project":"preeclampsia_genes","denotations":[{"id":"PD-PreeclampsiaGenes-B_T1","span":{"begin":60,"end":75},"obj":"HGNC:TYK2"},{"id":"PD-PreeclampsiaGenes-B_T2","span":{"begin":90,"end":113},"obj":"HGNC:PGF"}],"text":"To evaluate KRYPTOR assays for circulating soluble fms-like tyrosine kinase-1 (sFlt1) and placental growth factor (PlGF) in risk assessment of adverse outcomes in women with suspected preeclampsia."}

{"project":"sentences","denotations":[{"id":"TextSentencer_T3","span":{"begin":0,"end":197},"obj":"Sentence"},{"id":"T3","span":{"begin":0,"end":197},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"To evaluate KRYPTOR assays for circulating soluble fms-like tyrosine kinase-1 (sFlt1) and placental growth factor (PlGF) in risk assessment of adverse outcomes in women with suspected preeclampsia."}

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":90,"end":99},"obj":"http://purl.obolibrary.org/obo/UBERON_0001987"}],"text":"To evaluate KRYPTOR assays for circulating soluble fms-like tyrosine kinase-1 (sFlt1) and placental growth factor (PlGF) in risk assessment of adverse outcomes in women with suspected preeclampsia."}